AlloVir announces 1-for-23 reverse stock split effective Jan 15, 2025

Kalaris Therapeutics, Inc.

Board approved 1-for-23 reverse stock split; effective 4:05 PM ET Jan 15, 2025.
Stock to trade on split-adjusted basis on Nasdaq from Jan 16, 2025; CUSIP 019818202.
No fractional shares; cash payment in lieu at closing price on Jan 15.
Reverse split authorized by stockholders at special meeting on Jan 9, 2025 in connection with proposed merger with Kalaris Therapeutics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.